BiocurePharm about to release biosimilar for macular degeneration, waiting for patent expiration
From the year of 2018, the price of macular degeneration treatments will significantly drop. This is because the patent of ranibizumab, the main substance of a treatment for macular degeneration, will be expiring in 2017, allowing other companies to manufacture its biosimilars.
According to the ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
